Skip to content

XOMA Corporation XOMA Earnings yield

Earnings yield at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
3.9%+2.4pp
Royalty Pharma logo
Royalty PharmaRPRX
4%-4.1pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
13.7%+9.2pp
Innoviva, Inc. logo
Innoviva, Inc.INVA
29.2%+25.4pp
Zymeworks logo
ZymeworksZYME
-5.5%-2.1pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-29.6%+144pp

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
Enterprise value$784.29M+152%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Calculated from XOMA Corporation’s reported figures.

Based on trailing twelve months.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's earnings yield?
XOMA Corporation (XOMA) reported earnings yield of 9.1% in Q1 2026.
How has XOMA Corporation's earnings yield changed year-over-year?
XOMA Corporation's earnings yield increased by 855.9% year-over-year, from -1.2% to 9.1%.
What is the long-term trend for XOMA Corporation's earnings yield?
Over 5 years (2020 to 2025), XOMA Corporation's earnings yield has grown at a 29.3% compound annual growth rate (CAGR), from 2.7% to 9.6%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.